- Home
- VINC vs NLSP Comparison
VINC vs NLSP Comparison
Compare VINC & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VINC
- NLSP
- Stock Information
- Founded
- VINC 2019
- NLSP 2015
- Country
- VINC United States
- NLSP Switzerland
- Employees
- VINC N/A
- NLSP N/A
- Industry
- VINC Biotechnology: Pharmaceutical Preparations
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- VINC Health Care
- NLSP Health Care
- Exchange
- VINC Nasdaq
- NLSP Nasdaq
- Market Cap
- VINC 6.2M
- NLSP 5.2M
- IPO Year
- VINC N/A
- NLSP 2021
- Fundamental
- Price
- VINC $0.22
- NLSP $2.00
- Analyst Decision
- VINC Buy
- NLSP
- Analyst Count
- VINC 2
- NLSP 0
- Target Price
- VINC $2.00
- NLSP N/A
- AVG Volume (30 Days)
- VINC 557.0K
- NLSP 450.1K
- Earning Date
- VINC 11-12-2024
- NLSP 12-31-2024
- Dividend Yield
- VINC N/A
- NLSP N/A
- EPS Growth
- VINC N/A
- NLSP N/A
- EPS
- VINC N/A
- NLSP N/A
- Revenue
- VINC N/A
- NLSP N/A
- Revenue This Year
- VINC N/A
- NLSP N/A
- Revenue Next Year
- VINC N/A
- NLSP N/A
- P/E Ratio
- VINC N/A
- NLSP N/A
- Revenue Growth
- VINC N/A
- NLSP N/A
- 52 Week Low
- VINC $0.18
- NLSP $1.73
- 52 Week High
- VINC $9.37
- NLSP $24.32
- Technical
- Relative Strength Index (RSI)
- VINC 38.03
- NLSP 22.65
- Support Level
- VINC $0.19
- NLSP $1.75
- Resistance Level
- VINC $0.23
- NLSP $2.13
- Average True Range (ATR)
- VINC 0.03
- NLSP 0.29
- MACD
- VINC 0.00
- NLSP -0.03
- Stochastic Oscillator
- VINC 29.74
- NLSP 4.23
About VINC Vincerx Pharma Inc.
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.